IPM Take
Japan has crossed the regulatory line on molecular residual disease testing in colorectal cancer. Now comes the harder part.
A test can be authorised, clinically supported and available through a laboratory network, yet still fail to change care if pricing, reimbursement and clinical workflows lag behind. MRD testing only becomes personalised medicine when the result reaches the oncologist, informs a decision and is financially reachable for the patient and system.
Executive Summary
Natera announced in June 2026 that Signatera received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for colorectal cancer in the adjuvant setting. The company describes Signatera as the first PMDA-approved molecular residual disease test in Japan.
Natera expects commercial launch by the end of 2026, subject to final pricing determination. The company said approval was supported by evidence from the GALAXY programme within CIRCULATE-Japan, and that SRL, a national reference laboratory network, will support commercialisation in Japan.
Why it matters
- Patients / advocates: Post-surgery uncertainty is one of the hardest parts of colorectal cancer care. MRD testing may help make follow-up and treatment decisions more individualised.
- Clinicians: A test result only matters when it is integrated into adjuvant decision-making, surveillance and discussion with the patient.
- Diagnostics / pathology: National laboratory readiness will shape turnaround time, quality assurance and geographic equity.
- Payers: Final pricing will determine whether regulatory approval becomes a routine-care option or remains limited to selected settings.
A molecular residual disease result is not just another laboratory number.
After colorectal cancer surgery, patients and clinicians are often left with a difficult question: has the cancer truly gone, or is microscopic disease still present beyond what imaging can see? MRD testing is designed to bring more information into that uncertain space.
Japan’s PMDA approval of Signatera for colorectal cancer in the adjuvant setting is therefore a meaningful precision-oncology milestone. It creates a formal regulatory route for a personalised circulating tumour DNA test in one of the world’s largest colorectal cancer markets.
But regulatory approval is only the first gate.
Natera has stated that commercial launch depends on final pricing. That is where access becomes real. Will the test be reimbursed? Will it be offered beyond leading academic centres? Will results return quickly enough to inform adjuvant treatment decisions? Will clinicians have clear guidance on what to do when a patient is MRD-positive or MRD-negative?
The evidence is moving fast. The system still needs to catch up.
For IPM, this is the central lesson. Molecular testing does not change cancer care because a regulator approves it. It changes care when affordability, laboratory delivery, clinical confidence and patient communication all work together.
